NEW YORK – Diagnostics software and services company Aranscia said on Wednesday that it has acquired select assets of pharmacogenomics decision support company YouScript from Invitae for an undisclosed amount.
YouScript provides real-time medication risk and PGx information to help healthcare providers and organizations build personalized medication management programs.
Invitae had decided to sell YouScript earlier this year after choosing to discontinue PGx testing amid a broader restructuring and layoffs.
The company had originally acquired YouScript in 2020 for $79.3 million.
YouScript joins Aranscia's portfolio of companies, which includes PGx and population health insights company 2bPrecise, diagnostic services support company SinguLab, and molecular diagnostics laboratory AccessDx Laboratory, which specializes in PGx operations.
"As one of the foundational innovators in PGx, YouScript has long served as a model contributor to advancing the practical utilization of PGx for clinical professionals as well as measuring the profound impact of PGx programs in improving overall healthcare outcomes," Joe Spinelli, chief strategy officer at Houston-based Aranscia, said in a statement. "We’re committed to supporting the continued success of YouScript at Aranscia and look forward to collaboration with our other portfolio assets to help YouScript efficiently support clinical PGx programs for providers and organizations around the world."
"The Aranscia team shares our view that clinical decision support and workflow technologies are a necessity for precision medicine programs to scale, and we’re thrilled to be working together to make pharmacogenomics seamless and simple for patients and providers," added Kristine Ashcraft, founder of YouScript.